Dementia With Lewy Bodies Clinical Trial
Official title:
A Pragmatic Randomized Trial Comparing Antipsychotics in Lewy Body Disease
The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).
Psychosis (hallucinations and delusions) is a common problem in Parkinson's disease (PD) and dementia with Lewy bodies (DLB). PD is a common neurodegenerative disorder that causes movement, cognitive, and psychiatric symptoms. DLB is a similar disorder, though causes more severe cognitive and psychiatric problems. Psychosis is highly prevalent among people with PD and DLB, often manifesting as visual hallucinations or paranoid delusions. Up to 60% of people with PD will experience psychosis over the course of their disease. Psychosis is associated with increased mortality, caregiver burden, and poorer quality of life. More study is needed to determine the best way to treat psychosis in PD and DLB. Currently, both quetiapine and pimavanserin are used in clinical practice for psychosis in PD and DLB. However, few comparison studies have been done and it is unclear if one medication is superior to the other. This will be a clinical trial comparing quetiapine and pimavanserin among patients with psychosis due to PD or DLB requiring initiation of a medication. Patients will be randomized to quetiapine or pimavanserin and improvement in psychosis at 6 months will be compared between the groups. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03996460 -
K0706 for Patients Diagnosed With Dementia With Lewy Bodies
|
Phase 2 | |
| Recruiting |
NCT04335994 -
ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing
|
N/A | |
| Recruiting |
NCT02194816 -
Modifiable Variables in Parkinsonism (MVP)
|
||
| Active, not recruiting |
NCT01208675 -
The Swedish BioFINDER Study
|
||
| Completed |
NCT03538522 -
A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
|
Phase 2 | |
| Recruiting |
NCT03672448 -
The China Longitudinal Aging Study of Cognitive Impairment
|
||
| Completed |
NCT01340001 -
Effects of Nucleus Basalis of Meynert Stimulation on Cognitive Disorders in Dementia With Lewy Bodies
|
N/A | |
| Not yet recruiting |
NCT04760860 -
Terazosin for Dementia With Lewy Bodies
|
Phase 1/Phase 2 | |
| Terminated |
NCT02928445 -
Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension
|
Phase 2/Phase 3 | |
| Completed |
NCT02910102 -
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
|
Phase 2 | |
| Terminated |
NCT02871427 -
Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder
|
Phase 2 | |
| Completed |
NCT05188105 -
Alpha tACS in Dementia With Lewy Bodies
|
N/A | |
| Active, not recruiting |
NCT04167813 -
Trial of Ondansetron as a Parkinson's HAllucinations Treatment
|
Phase 2 | |
| Enrolling by invitation |
NCT04954183 -
Development of an EEG Diagnostic for Alzheimer's Disease
|
||
| Recruiting |
NCT05326750 -
Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases
|
N/A | |
| Completed |
NCT01023672 -
"Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies"
|
Phase 4 | |
| Completed |
NCT03907748 -
Home-based Family Caregiver-delivered Music and Reading Interventions for People With Dementia
|
N/A | |
| Completed |
NCT04649164 -
Learning to PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia
|
N/A | |
| Recruiting |
NCT03924414 -
Trial of Parkinson's And Zoledronic Acid
|
Phase 4 | |
| Completed |
NCT05885620 -
SAMi Intervention Study to Evaluate Smartwatch Interventions in Persons With MCI and Dementia
|
N/A |